BlackRock
KITE

BlackRock’s Kite Pharma, Inc. KITE Stock Holding History

BlackRock’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,137,189
Closed -$744M – 5103
2017
Q3 		$744M Buy
4,137,189
+141,917
+4% +$19.8M 0.04% 487
2017
Q2 		$414M Buy
3,995,272
+373,301
+10% +$30.5M 0.02% 750
2017
Q1 		$284M Buy
3,621,971
+3,618,566
+106,272% +$224M 0.02% 1014
2016
Q4 		$152K Sell
3,405
-707
-17% -$34.7K ﹤0.01% 2311
2016
Q3 		$229K Buy
4,112
+90
+2% +$5.01K ﹤0.01% 2084
2016
Q2 		$201K Buy
4,022
+1,926
+92% +$94.6K ﹤0.01% 2102
2016
Q1 		$97K Buy
2,096
+813
+63% +$39.4K ﹤0.01% 2012
2015
Q4 		$79K Buy
1,283
+601
+88% +$42.3K ﹤0.01% 1853
2015
Q3 		$38K Sell
682
-117
-15% -$7.36K ﹤0.01% 2044
2015
Q2 		$49K Buy
799
+576
+258% +$32.9K ﹤0.01% 1988
2015
Q1 		$13K Hold
223
– – ﹤0.01% 2606
2014
Q4 		$13K Hold
223
– – ﹤0.01% 2622
2014
Q3 		$6K Buy
+223
New +$5.52K ﹤0.01% 3040

BlackRock's KITE Position: Q4 2017 in Review

BlackRock sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 4,137,189 shares — an estimated $744M sold.

BlackRock first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $744M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • BlackRock reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • BlackRock sold 4,137,189 Kite Pharma, Inc. shares in Q4 2017, an estimated $744M.
  • BlackRock first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
  • BlackRock's Kite Pharma, Inc. position peaked at $744M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on BlackRock's 13F filing for Q4 2017, filed 9 Feb 2018.